Krystal Biotech, Inc. (KRYS) Q3 2018 Earnings Results

Krystal Biotech Misses on EPS — Stock Down 1.94%

Krystal Biotech's earnings report showed a loss per share of $0.26, with no revenue figures disclosed. The stock reacted negatively, declining by 1.94%. The lack of detailed financial guidance or revenue updates may have contributed to investor caution.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.26	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Neutral

Management emphasized the importance of their clinical programs and ongoing research. However, they did not provide specific updates on financial performance.

Management did not provide specific revenue figures or guidance for future quarters.

The focus remains on ongoing clinical trials and product development.

Krystal Biotech Misses on EPS — Stock Down 1.94%

Key numbers

Management commentary

Krystal Biotech, Inc.

More earnings this week

Krystal Biotech Misses on EPS — Stock Down 1.94%

Key numbers

Management commentary